The 10-second takeaway
For the quarter ended Dec. 31 (Q2), Molex beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.
Margins dropped across the board.
Molex chalked up revenue of $967.7 million. The 13 analysts polled by S&P Capital IQ expected to see sales of $949.6 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $857.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.39. The 14 earnings estimates compiled by S&P Capital IQ anticipated $0.38 per share. GAAP EPS of $0.39 for Q2 were 8.3% higher than the prior-year quarter's $0.36 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 29.9%, 80 basis points worse than the prior-year quarter. Operating margin was 11.2%, 40 basis points worse than the prior-year quarter. Net margin was 7.3%, 20 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $935.1 million. On the bottom line, the average EPS estimate is $0.38.
Next year's average estimate for revenue is $3.79 billion. The average EPS estimate is $1.60.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 134 members out of 149 rating the stock outperform, and 15 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give Molex a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Molex is hold, with an average price target of $26.77.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Molex. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Molex to My Watchlist.